NHS guidelines on familial breast cancer care:
This article was originally published in Clinica
Breast cancer care in England and Wales is subject to new guidelines on the provision of mammography, genetic testing and risk-reducing surgery in cases of so-called "familial" risk. Mammography should be performed subject to clearly advising the patient on the implications of early detection, the National Institute for Clinical Excellence (NICE) and the National Collaborating Centre for Primary Care (NCCPC) recommend. They also urge the NHS to recognise that genetic testing and risk-reducing surgery are appropriate in only a small proportion of women from high-risk families. The guidance also highlights the need for greater public awareness of risk, notably that the great majority of women with a family history do not fall into a high-risk category.
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.